JP2006045113A - Phosphoric acid ester - Google Patents

Phosphoric acid ester Download PDF

Info

Publication number
JP2006045113A
JP2006045113A JP2004228056A JP2004228056A JP2006045113A JP 2006045113 A JP2006045113 A JP 2006045113A JP 2004228056 A JP2004228056 A JP 2004228056A JP 2004228056 A JP2004228056 A JP 2004228056A JP 2006045113 A JP2006045113 A JP 2006045113A
Authority
JP
Japan
Prior art keywords
phosphoric acid
acid ester
sphingomyelin
reaction
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004228056A
Other languages
Japanese (ja)
Inventor
Shigeo Katsumura
成雄 勝村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KEMIKUREA KK
Kwansei Gakuin Educational Foundation
Chemicrea Inc
Original Assignee
KEMIKUREA KK
Kwansei Gakuin Educational Foundation
Chemicrea Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KEMIKUREA KK, Kwansei Gakuin Educational Foundation, Chemicrea Inc filed Critical KEMIKUREA KK
Priority to JP2004228056A priority Critical patent/JP2006045113A/en
Publication of JP2006045113A publication Critical patent/JP2006045113A/en
Pending legal-status Critical Current

Links

Abstract

<P>PROBLEM TO BE SOLVED: To provide a new phosphoric acid ester of a sphingosine derivative, useful as a synthetic raw material such as sphingomyelin, etc. <P>SOLUTION: This phosphoric acid ester is expressed by general formula (I) [wherein, R<SP>1</SP>, R<SP>2</SP>are each an alkyl which may have a substituent; R<SP>3</SP>is a lower alkyl; and Y is a halogen atom]. By using the new phosphoric acid ester, without performing a protection of hydroxy group, etc., it is possible to convert the ester to another phosphoric acid ester, and it becomes possible to produce sphingomyelin which is effective for a drug delivery system, etc., easily in a smaller number of processes as compared with those of the conventional reaction processes. <P>COPYRIGHT: (C)2006,JPO&NCIPI

Description

本発明はスフィンゴシン誘導体のリン酸エステル類に関するものであり、詳細にはドラッグデリバリーシステム等に有効なスフィンゴミエリンなどの合成原料として有用な物質に関するものである。   The present invention relates to phosphate esters of sphingosine derivatives, and more particularly to substances useful as synthetic raw materials such as sphingomyelin effective for drug delivery systems.

従来、スフィンゴシン誘導体からスフィンゴミエリン等のリン酸エステル類へ変換する方法としては、クロロ−N,N−ジイソプロピルアミノメトキシホスフィンを用いる方法(たとえば非特許文献1)、エチレンクロロホスファイトを用いる方法(たとえば非特許文献2)、環状クロロホスフェートを用いる方法(たとえば非特許文献3)が知られている。
A. L. Weis, Chem. Phys. Lip., 102, 3-12 (1999) H. S. Byun, R. K. Erukulla, and R. K. Bittman, J. Org. Chem., 59, 6495-6498 (1994) Z. Dong and J. A. Butcher, Tetrahedron Lett., 32, 5291-5294 (1991)
Conventionally, as a method for converting a sphingosine derivative into a phosphate ester such as sphingomyelin, a method using chloro-N, N-diisopropylaminomethoxyphosphine (for example, Non-Patent Document 1), a method using ethylene chlorophosphite (for example, Non-Patent Document 2) and methods using cyclic chlorophosphate (for example, Non-Patent Document 3) are known.
AL Weis, Chem. Phys. Lip., 102, 3-12 (1999) HS Byun, RK Erukulla, and RK Bittman, J. Org. Chem., 59, 6495-6498 (1994) Z. Dong and JA Butcher, Tetrahedron Lett., 32, 5291-5294 (1991)

しかしながら、非特許文献1に記載の方法では、ヒドロキシル基の保護が必要であり、反応後トシル酸コリンを反応させ、さらに酸化してリン酸エステルとし、さらに脱メチル化、脱シリル化しなければならず、煩雑で工程数が多いという問題がある。非特許文献2記載の方法では、反応後臭素の酸化的付加、加水分解、トリメチルアンモニウムイオンの導入を行わねばならず、この方法もやはり煩雑で工程数が多いという問題がある。非特許文献3に記載の方法では、ヒドロキシル基の保護・脱保護が必要であり、反応後無水トリメチルアミンを反応させてホスホコリンに誘導しなければならず、この方法もやはり煩雑である。   However, in the method described in Non-Patent Document 1, it is necessary to protect the hydroxyl group. After the reaction, choline tosylate is reacted, further oxidized to a phosphate ester, and further demethylated and desilylated. However, there is a problem that the number of steps is complicated and complicated. In the method described in Non-Patent Document 2, bromine oxidative addition, hydrolysis, and introduction of trimethylammonium ions must be performed after the reaction, and this method also has a problem that it is complicated and requires a large number of steps. In the method described in Non-Patent Document 3, it is necessary to protect and deprotect the hydroxyl group. After the reaction, anhydrous trimethylamine must be reacted to induce phosphocholine, which is also complicated.

本発明はスフィンゴミエリンなどの合成原料として有用な新規スフィンゴシン誘導体リン酸エステル類を提供することを目的とするものである。   An object of the present invention is to provide novel sphingosine derivative phosphates useful as a raw material for synthesis of sphingomyelin and the like.

本発明者らは、かかる問題を解決すべく鋭意研究を行った結果、スフィンゴミエリン等の合成中間体として有用な新規リン酸エステル類を見出し、本発明を完成するに至った。   As a result of intensive studies to solve such problems, the present inventors have found novel phosphate esters useful as synthetic intermediates such as sphingomyelin and have completed the present invention.

すなわち本発明の新規リン酸エステル類は、下記一般式(I)

Figure 2006045113
That is, the novel phosphate esters of the present invention have the following general formula (I)
Figure 2006045113

(式中、RはおよびRは置換基を有していてもよいアルキル基であり、Rは低級アルキル基であり、Yはハロゲン原子を表す。)で表されることを特徴とするものである。 (Wherein R 1 and R 2 are alkyl groups optionally having substituents, R 3 is a lower alkyl group, and Y represents a halogen atom). To do.

本発明の新規リン酸エステル類を用いれば、ヒドロキシル基等の保護を行うことなくリン酸エステル類へ簡便に変換することができ、ドラッグデリバリーシステム等に有効なスフィンゴミエリンを、従来の反応工程に比べて工程数を少なく、かつ簡易に製造することが可能である。   If the novel phosphate esters of the present invention are used, they can be easily converted to phosphate esters without protecting the hydroxyl group and the like, and sphingomyelin effective for drug delivery systems and the like can be converted into conventional reaction steps. Compared to the number of steps, it can be easily manufactured.

本発明の新規リン酸エステル類は、一般式(I)

Figure 2006045113
The novel phosphate esters of the present invention have the general formula (I)
Figure 2006045113

(式中、RおよびRは置換基を有していてもよいアルキル基であり、Rは低級アルキル基であり、Yはハロゲン原子を表す。)で表されることを特徴とする。 Wherein R 1 and R 2 are alkyl groups which may have a substituent, R 3 is a lower alkyl group, and Y represents a halogen atom. .

ここで上記低級アルキル基とは、枝分かれを有していてもよい炭素数1から8のアルキル基であり、メチル基、エチル基、プロピル基、イソプロピル基、ブチル基、sec−ブチル基、t−ブチル基、ペンチル基等を例示することができる。   Here, the lower alkyl group is an alkyl group having 1 to 8 carbon atoms which may have a branch, and includes a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, a sec-butyl group, t- A butyl group, a pentyl group, etc. can be illustrated.

上記アルキル基とは、反応に関与しない置換基や枝分かれを有していてもよい炭素数1から20のアルキル基である。ハロゲン原子とは、フッ素原子、塩素原子、臭素原子、ヨウ素原子である。   The said alkyl group is a C1-C20 alkyl group which may have a substituent and branch which do not participate in reaction. A halogen atom is a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom.

本発明の一般式(I)で表されるリン酸エステル類は、下記に示すように、公知の化合物(重成俊彦、箱木敏和、勝村成雄、日本化学会第84春季年会2J2−49(2004))から、たとえば、N原子上の脱保護の後、アシル化することにより製造することができる。

Figure 2006045113
As shown below, the phosphate esters represented by the general formula (I) of the present invention are known compounds (Toshihiko Shigenari, Toshikazu Hakogi, Naruo Katsumura, The Chemical Society of Japan 84th Spring Annual Meeting 2J2-49. (2004)), for example, can be prepared by deprotection on the N atom followed by acylation.
Figure 2006045113

脱保護過程は、通常酸存在下に行うことが好ましい。利用できる酸としては、塩酸、硫酸等の鉱酸、トリフルオロ酢酸、トリフルオロメタンスルホン等の有機酸を好適に用いることができる。   The deprotection process is usually preferably performed in the presence of an acid. As the acid that can be used, mineral acids such as hydrochloric acid and sulfuric acid, and organic acids such as trifluoroacetic acid and trifluoromethanesulfone can be suitably used.

アシル化過程は、対応するカルボン酸の無水物、酸クロリド、エステル等を用いて好適に行うことができる。アシル化過程の実施にあたっては塩基を用いることが好ましい。用いることができる塩基としては、炭酸カリウム、炭酸水素ナトリウム等の無機塩基、トリエチルアミン、ジイソプロピルエチルアミン、ピリジン、イミダゾール等の有機塩基を好適に利用することができる。   The acylation process can be suitably performed using a corresponding carboxylic acid anhydride, acid chloride, ester or the like. A base is preferably used in carrying out the acylation process. As the base that can be used, inorganic bases such as potassium carbonate and sodium hydrogen carbonate, and organic bases such as triethylamine, diisopropylethylamine, pyridine, and imidazole can be preferably used.

反応の実施にあたっては、反応に関与しない溶媒中で行うことが好ましく、ベンゼン、トルエン、キシレン、ヘキサン、シクロヘキサン等の炭化水素系溶媒、N,N−ジメチルホルムアミド、ジメチルスルホキシド等の非プロトン性極性溶媒、酢酸エチル、酢酸ブチル等のエステル系溶媒、テトラヒドロフラン、1,4−ジオキサン、1,2−ジメトキシエタン、ジグライム、トリグライムジエチレングリコールモノメチルエーテル等のエーテル系溶媒、アセトン、メチルエチルケトン、メチルイソブチルケトン等のケトン系溶媒、アセトニトリル等のニトリル系溶媒、ジクロロメタン、1,2−ジクロロエタン等のハロゲン系溶媒、水媒体並びにこれらの混合溶媒等が挙げられるが、好ましくはテトラヒドロフラン、1,4−ジオキサン、1,2−ジメトキシエタン、ジグライム、トリグライムジエチレングリコールモノメチルエーテル等のエーテル系溶媒が望ましい。   The reaction is preferably carried out in a solvent that does not participate in the reaction, hydrocarbon solvents such as benzene, toluene, xylene, hexane and cyclohexane, aprotic polar solvents such as N, N-dimethylformamide and dimethyl sulfoxide. , Ester solvents such as ethyl acetate and butyl acetate, ether solvents such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, diglyme and triglyme diethylene glycol monomethyl ether, and ketones such as acetone, methyl ethyl ketone and methyl isobutyl ketone Solvent, nitrile solvent such as acetonitrile, halogen solvent such as dichloromethane and 1,2-dichloroethane, aqueous medium and mixed solvent thereof, and the like, preferably tetrahydrofuran, 1,4-dioxane, , 2-dimethoxyethane, diglyme, ether solvents such as triglyme diethylene glycol monomethyl ether is preferred.

反応温度は、−40℃ないし80℃の温度範囲から適宜選択することができるが、反応速度ならびに経済的観点から0℃ないし室温の範囲が好ましい。
以下、本発明を実施例および参考例によりさらに詳しく説明する。
The reaction temperature can be appropriately selected from a temperature range of −40 ° C. to 80 ° C., but a range of 0 ° C. to room temperature is preferred from the viewpoint of reaction rate and economics.
Hereinafter, the present invention will be described in more detail with reference to Examples and Reference Examples.

(実施例1)

Figure 2006045113
Example 1
Figure 2006045113

2−ブロモエチル(2−t−ブチルオキシカルボニルアミノ−3−ヒドロキシオクタデカ−4−エニル)メチルフォスフェート(上記2)(2-Bromoethyl(2-tert-butyloxycarbonylamino-3-hydroxyoctadec-4-enyl)(methyl)phosphate :500 mg, 0.833 mmol )の塩化メチレン( 4.16 ml )溶液に0℃でトリフルオロ酢酸( 1.67 ml )を加え、1.5時間攪拌した。反応溶液に1N NaOH水溶液を加え、中和した後、クロロホルムで抽出し、有機層を飽和食塩水で洗浄した。これを無水硫酸マグネシウムで乾燥後、減圧濃縮を行った。残渣をTHF、H2O( 8.32ml, 1:1 )で溶解し、0℃で炭酸カリウム( 575 mg, 4.16 mmol )、パルミトイルクロリド( 0.28 ml, 0.916 mmol ) を順次加え、15分攪拌した。反応混合液を飽和塩化アンモニウム水溶液で中和し、クロロホルムで抽出した。有機層を飽和食塩水で洗浄し、無水硫酸マグネシウムで乾燥、減圧濃縮を行った。残渣をシリカゲルクロマトグラフィー(クロロホルムに0%〜10% のメタノールを溶かしたもの)により分離・精製し、2−ブロモメチル(2−ヘキサデカノイルアミノ−3−ヒドロキシオクタデカ−4−エニル)メチルホスフェート(上記3)(2-Bromoethyl(2-hexadecanoylamino-3-hydroxyoctadec-4-enyl)(methyl)phosphate:522 mg, 85% )を得た。2−ブロモメチル(2−ヘキサデカノイルアミノ−3−ヒドロキシオクタデカ−4−エニル)メチルホスフェート(上記3)のIR、1H NMR、13C NMRデータを以下に示す。 2-Bromoethyl (2-tert-butyloxycarbonylamino-3-hydroxyoctadec-4-enyl) (2-Bromoethyl (2-tert-butyloxycarbonylamino-3-hydroxyoctadec-4-enyl) ( Methyl chloride (500 mg, 0.833 mmol) in methylene chloride (4.16 ml) was added trifluoroacetic acid (1.67 ml) at 0 ° C. and stirred for 1.5 hours. 1N NaOH aqueous solution was added to the reaction solution for neutralization, followed by extraction with chloroform, and the organic layer was washed with saturated brine. This was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was dissolved in THF and H 2 O (8.32 ml, 1: 1), potassium carbonate (575 mg, 4.16 mmol) and palmitoyl chloride (0.28 ml, 0.916 mmol) were sequentially added at 0 ° C., and the mixture was stirred for 15 minutes. The reaction mixture was neutralized with saturated aqueous ammonium chloride and extracted with chloroform. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was separated and purified by silica gel chromatography (0 to 10% methanol in chloroform), and 2-bromomethyl (2-hexadecanoylamino-3-hydroxyoctadec-4-enyl) methyl phosphate ( 3) (2-Bromoethyl (2-hexadecanoylamino-3-hydroxyoctadec-4-enyl) (methyl) phosphate: 522 mg, 85%) was obtained. IR, 1 H NMR, and 13 C NMR data of 2-bromomethyl (2-hexadecanoylamino-3-hydroxyoctadec-4-enyl) methyl phosphate (above 3) are shown below.

IR (KBr disk): 3291, 2917, 1647, 1547, 1468, 1269, 1047 cm-1
1H NMR (CDCl3, 400 MHz) δ: 6.25 ( d, J =7.3 Hz, 1H), 5.75 ( td, J = 6.8, 15.1 Hz, 1H ), 5.48 ( dd, J =6.6, 15.4 Hz, 1H ), 4.33 ( m, 3H ), 4.17 ( m, 3H ), 3.81 ( d, J =11.2 Hz, 3/2H ), 3.80 ( d, J =11.2 Hz, 3/2H ), 3.55 ( t, J =6.1 Hz, 2H ), 2.19 ( dt, J =1.7, 7.1 Hz, 2H ), 2.03 ( td, J =7.1, 1.7 Hz, 2H ), 1.61 ( m, 2H ), 1.26 ( m, 46 H ), 0.88 ( t, J =6.6 Hz, 6 H )
13C NMR (CDCl3, 100MHz) δ: 173.6, 134.8, 128.5, 72.4, 67.2 ( m ), 66.8 ( d, JC-P = 5.0 Hz ), 54.77 ( d, JC-P = 5.8 Hz, 1/2 C ), 54.74 ( d, JC-P = 5.8 Hz, 1/2 C ), 53.7 ( d, JC-P = 5.8 Hz ), 36.7, 32.3, 31.9, 29.7, 29.5, 29.4, 29.3, 29.3, 29.1, 25.7, 22.6, 14.1
IR (KBr disk): 3291, 2917, 1647, 1547, 1468, 1269, 1047 cm -1
1 H NMR (CDCl 3 , 400 MHz) δ: 6.25 (d, J = 7.3 Hz, 1H), 5.75 (td, J = 6.8, 15.1 Hz, 1H), 5.48 (dd, J = 6.6, 15.4 Hz, 1H ), 4.33 (m, 3H), 4.17 (m, 3H), 3.81 (d, J = 11.2 Hz, 3 / 2H), 3.80 (d, J = 11.2 Hz, 3 / 2H), 3.55 (t, J = 6.1 Hz, 2H), 2.19 (dt, J = 1.7, 7.1 Hz, 2H), 2.03 (td, J = 7.1, 1.7 Hz, 2H), 1.61 (m, 2H), 1.26 (m, 46 H), 0.88 (t, J = 6.6 Hz, 6 H)
13 C NMR (CDCl 3 , 100 MHz) δ: 173.6, 134.8, 128.5, 72.4, 67.2 (m), 66.8 (d, J CP = 5.0 Hz), 54.77 (d, J CP = 5.8 Hz, 1/2 C) , 54.74 (d, J CP = 5.8 Hz, 1/2 C), 53.7 (d, J CP = 5.8 Hz), 36.7, 32.3, 31.9, 29.7, 29.5, 29.4, 29.3, 29.3, 29.1, 25.7, 22.6, 14.1

(参考例1)

Figure 2006045113
(Reference Example 1)
Figure 2006045113

2−ブロモメチル(2−ヘキサデカノイルアミノ−3−ヒドロキシオクタデカ−4−エニルメチルホスフェート(上記3:502 mg, 0.679 mmo ) のメタノール ( 8.36 ml )溶液に室温で無水のトリメチルアミン ( 5.40 ml ) を加え、同温で2日間攪拌した。反応混合物を水で希釈し、クロロホルム、メタノールで抽出し、有機層を減圧濃縮した。残渣をシリカゲルクロマトグラフィー(メタノール:クロロホルム=1:9〜メタノール:クロロホルム:水=65:25:4 )により分離・精製し、スフィンゴミエリン(上記4)を得た。スフィンゴミエリンのIR、1H NMRデータを以下に示す。 To a solution of 2-bromomethyl (2-hexadecanoylamino-3-hydroxyoctadec-4-enylmethyl phosphate (3: 502 mg, 0.679 mmo) in methanol (8.36 ml) at room temperature with anhydrous trimethylamine (5.40 ml). The reaction mixture was diluted with water, extracted with chloroform and methanol, and the organic layer was concentrated under reduced pressure.The residue was chromatographed on silica gel (methanol: chloroform = 1: 9 to methanol: chloroform: Separation and purification by water = 65: 25: 4) gave sphingomyelin (4) IR and 1 H NMR data of sphingomyelin are shown below.

IR(KBr disk): 3447, 2919, 1640, 1231, 1090 cm-1
1H NMR (CD3OD), 400MHz) δ: 5.71 (dtd, J=15.4, 6.6, 0.5Hz, 1H),
5.46 (ddt, J=15.4, 7.6, 1.5Hz, 1H), 4.28 (m, 2H), 4.14-3.88 (m, 4H),
3.63 (t, J=4.9Hz, 2H), 3.22 (s, 9H), 2.19 (m, 2H),
2.03 (dt, J=6.8, 6.8Hz, 2H), 1.59 (m, 2H), 1.29 (s, 46H),
0.90 (t, J=7.1Hz, 6H)
IR (KBr disk): 3447, 2919, 1640, 1231, 1090 cm -1
1 H NMR (CD3OD), 400MHz) δ: 5.71 (dtd, J = 15.4, 6.6, 0.5Hz, 1H),
5.46 (ddt, J = 15.4, 7.6, 1.5Hz, 1H), 4.28 (m, 2H), 4.14-3.88 (m, 4H),
3.63 (t, J = 4.9Hz, 2H), 3.22 (s, 9H), 2.19 (m, 2H),
2.03 (dt, J = 6.8, 6.8Hz, 2H), 1.59 (m, 2H), 1.29 (s, 46H),
0.90 (t, J = 7.1Hz, 6H)

参考例1に示すように、本発明の新規リン酸エステル類を用いれば、ドラッグデリバリーシステム等に有効なスフィンゴミエリンを従来の反応工程に比べて工程数を少なく、かつ簡便に製造することが可能である。   As shown in Reference Example 1, by using the novel phosphate esters of the present invention, it is possible to easily produce sphingomyelin that is effective for drug delivery systems and the like with fewer steps than conventional reaction steps. It is.

Claims (1)

下記一般式(I)
Figure 2006045113
(式中、RはおよびRは置換基を有していてもよいアルキル基であり、Rは低級アルキル基であり、Yはハロゲン原子を表す。)で表されることを特徴とするリン酸エステル類。
The following general formula (I)
Figure 2006045113
(Wherein R 1 and R 2 are alkyl groups optionally having substituents, R 3 is a lower alkyl group, and Y represents a halogen atom). Phosphate esters.
JP2004228056A 2004-08-04 2004-08-04 Phosphoric acid ester Pending JP2006045113A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2004228056A JP2006045113A (en) 2004-08-04 2004-08-04 Phosphoric acid ester

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004228056A JP2006045113A (en) 2004-08-04 2004-08-04 Phosphoric acid ester

Publications (1)

Publication Number Publication Date
JP2006045113A true JP2006045113A (en) 2006-02-16

Family

ID=36024111

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004228056A Pending JP2006045113A (en) 2004-08-04 2004-08-04 Phosphoric acid ester

Country Status (1)

Country Link
JP (1) JP2006045113A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9643915B2 (en) 2013-03-15 2017-05-09 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
US9708354B2 (en) 2013-03-15 2017-07-18 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0193562A (en) * 1987-10-05 1989-04-12 Shionogi & Co Ltd Production of sphingosine derivative
JPH08500816A (en) * 1992-04-03 1996-01-30 ザ・バイオメンブレイン・インスティテュート Method for inhibiting cell activity by sphingosine-1-phosphate and its derivatives and mimetics, and method for synthesizing sphingosine-1-phosphate and its derivatives
JP2004175735A (en) * 2002-11-28 2004-06-24 Daiso Co Ltd Sphingomyelin analogue and method for producing the same
JP2004256456A (en) * 2003-02-26 2004-09-16 Nitto Kasei Co Ltd 2-bromoethyldialkyl phosphite, method for producing the same, and method for producing phosphoric ester derivative using the same
JP2005263774A (en) * 2004-02-18 2005-09-29 Daiso Co Ltd Photoaffinity-labeled sphingomyelin analogue and method for producing the same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0193562A (en) * 1987-10-05 1989-04-12 Shionogi & Co Ltd Production of sphingosine derivative
JPH08500816A (en) * 1992-04-03 1996-01-30 ザ・バイオメンブレイン・インスティテュート Method for inhibiting cell activity by sphingosine-1-phosphate and its derivatives and mimetics, and method for synthesizing sphingosine-1-phosphate and its derivatives
JP2004175735A (en) * 2002-11-28 2004-06-24 Daiso Co Ltd Sphingomyelin analogue and method for producing the same
JP2004256456A (en) * 2003-02-26 2004-09-16 Nitto Kasei Co Ltd 2-bromoethyldialkyl phosphite, method for producing the same, and method for producing phosphoric ester derivative using the same
JP2005263774A (en) * 2004-02-18 2005-09-29 Daiso Co Ltd Photoaffinity-labeled sphingomyelin analogue and method for producing the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6010044883, 重成 俊彦 他, "光アフィニティー標識化スフィンゴ脂質の創製", 日本化学会第84春期年会−講演予稿集II, 20040311, p.1019 *
JPN6010044885, 重成 俊彦 他, "蛍光標識化スフィンゴ脂質の創製", 第33回複素環化学討論会 講演要旨集, 20030919, p.42−43 *
JPN6010044886, 山本 哲也 他, "スフィンゴミエリンおよびスフィンゴシン−1−リン酸窒素類縁体の合成", 日本化学会第84春期年会−講演予稿集II, 20040311, p.1019 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9643915B2 (en) 2013-03-15 2017-05-09 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
US9708354B2 (en) 2013-03-15 2017-07-18 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins

Similar Documents

Publication Publication Date Title
Zafrani et al. Diethyl bromodifluoromethylphosphonate: a highly efficient and environmentally benign difluorocarbene precursor
EP2133356A1 (en) Process for production of phosphorus-containing -keto acid
JP6793187B2 (en) Phosphoramidart compound and its production method and crystals
EP3199537A1 (en) Processes and intermediates for preparing anti-hiv agents
JP2006045113A (en) Phosphoric acid ester
JP5639599B2 (en) Process for synthesizing β-glycerol phosphate
ES2741505T3 (en) Procedure for the preparation of abiraterone acetate and its intermediates
RU2346948C2 (en) DERIVATIVES OF 1-α-HALOGEN-2,2-DIFLUORO-2-DEOXY-D-RIBOFURANOSE AND METHOD OF THEIR OBTAINMENT
AU2006209556B2 (en) Process for production of 5-chloro-2,4-dihydroxypyridine
JP4742868B2 (en) (2R) -2-Propyloctanoic acid production method and intermediate
HU198947B (en) Process for producing purin-9-yl-alkoxy-methyl-phosphonic acid derivatives
JPS5936914B2 (en) Cephalosporin analogs
JP2006022019A (en) Sphingomyelin analogue and method for producing the same
AU705093B2 (en) Method for producing 3,4-dihydroxy-3-cyclobutene-1,2-dione
CA2574954C (en) 1-.alpha.-halo-2,2-difluoro-2-deoxy-d-ribofuranose derivatives and process for the preparation thereof
JP2007204384A (en) Optically active phosphoric acid derivative and method for producing optically active sphingosine 1-phosphate derivative using the same
JP4305010B2 (en) Phytosphingosine analogues and their production
KR101023455B1 (en) Method for Preparing Racemic or Optically Active ??Glycerophosphoryl choline
EP1430065A1 (en) Beta-ketophosphonates
JP4627625B2 (en) Method for producing N-acetylcytidines
JP2005263774A (en) Photoaffinity-labeled sphingomyelin analogue and method for producing the same
JP2004175735A (en) Sphingomyelin analogue and method for producing the same
JPWO2010079813A1 (en) Method for producing inosine derivative
JP2008100951A (en) Method for preparing 2-cyclopentadecenone
JP2010083798A (en) METHOD FOR PRODUCING omega-HYDROXY LONG-CHAIN FATTY ACID DERIVATIVE

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070713

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100810

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20100804

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110104